Autolus announces pricing of public offering (1167351)
10 February 2021 - 8:00PM
UK Regulatory
Arix Bioscience PLC (ARIX)
Autolus announces pricing of public offering
10-Feb-2021 / 09:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
=----------------------------------------------------------------------------------------------------------------------
Arix Bioscience plc
Autolus announces pricing of public offering
LONDON, 10 February 2021: Arix Bioscience plc ("Arix", LSE: ARIX), a global venture capital company focused on
investing in and building breakthrough biotech companies, today announces that its portfolio company, Autolus
Therapeutics plc ("Autolus", Nasdaq: AUTL), announced the pricing of its underwritten public offering in the United
States of 14,285,715 American Depositary Shares ("ADSs") representing 14,285,715 ordinary shares, at a public offering
price of USD7.00 per ADS, for total gross proceeds of approximately USD100.0 million. All ADSs sold in the offering were
offered by Autolus. In addition, Autolus has granted the underwriters a 30-day option to purchase up to an additional
2,142,857 ADSs at the public offering price, less underwriting discounts and commissions.
The announcement can be accessed on the Autolus website at https://www.autolus.com/investor-relations/news-and-events/
press-releases and full text of the announcement from Autolus is contained below.
[ENDS]
Enquiries
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0) 20 7290 1072
charlotte@arixbioscience.com
Optimum Strategic Communications
Supriya Mathur, Shabnam Bashir
+44 (0)20 3922 1906
optimum.arix@optimumcomms.com
About Arix Bioscience plc
Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech
companies around cutting-edge advances in life sciences.
We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate
their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth
phase of our industry to a broader range of investors. www.arixbioscience.com
Autolus Announces Pricing of Public Offering
LONDON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical
company developing next-generation programmed T cell therapies, today announced the pricing of an underwritten public
offering in the United States of 14,285,715 American Depositary Shares ("ADSs") representing 14,285,715 ordinary shares
at a public offering price of USD7.00 per ADS, for total gross proceeds of approximately USD100.0 million. All ADSs sold in
the offering were offered by Autolus. In addition, Autolus has granted the underwriters a 30-day option to purchase up
to an additional 2,142,857 ADSs at the public offering price, less underwriting discounts and commissions. The offering
is expected to close on February 12, 2021, subject to customary closing conditions.
J.P. Morgan and Wells Fargo Securities are acting as joint bookrunners for the offering. Kempen & Co, Mizuho Securities
and Needham & Company are acting as co-managers.
The securities are being offered pursuant to an effective shelf registration statement that was previously filed with
the Securities and Exchange Commission ("SEC"). A preliminary prospectus supplement to the prospectus describing the
terms of the offering was filed with the SEC on February 8, 2021, and a final prospectus supplement will be filed with
the SEC. The offering will be made only by means of a written prospectus and prospectus supplement that form a part of
the registration statement, which, for the avoidance of doubt, will not constitute a "prospectus" for the purposes of
the Regulation (EU) 2017/1129 and has not been reviewed by any competent authority in any member state in the European
Economic Area. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering
may be obtained for free from either of the joint book-running managers for the offering, J.P. Morgan Securities LLC, c
/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at +1 866 803 9204 or
by email at prospectus-eq_fi@jpmchase.com; or Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 500
West 33rd Street, New York, New York, 10001, at (800) 326-5897 or email a request to cmclientsupport@wellsfargo.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall
not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of that jurisdiction.
About Autolus
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is
engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize
cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product
candidates in development for the treatment of hematological malignancies and solid tumors.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the "safe harbor" provisions of
the Private Securities Litigation Reform Act of 1995, including statements with regard to Autolus' expectations
regarding the completion of the proposed securities offering. Words such as "anticipates," "believes," "expects,"
"intends," "projects," and "future" or similar expressions are intended to identify forward-looking statements. These
forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions and no
assurance can be given that the proposed securities offering discussed above will be consummated on the terms described
or at all. Completion of the proposed offering and the terms thereof are subject to numerous factors, many of which are
beyond the control of Autolus, including, without limitation, market conditions, failure of customary closing
conditions and the risk factors and other matters set forth in Autolus' Annual Report on Form 20-F for the year ended
December 31, 2019 and other filings Autolus makes with the SEC from time to time. Autolus undertakes no obligation to
publicly update or revise any forward-looking statements, whether as a result of new information, future events or
otherwise, except as may be required by law.
Contacts:
Lucinda Crabtree, Ph.D.
Vice President, Investor Relations and Corporate Communications
+44 (0)7587 372 619
l.crabtree@autolus.com
Julia Wilson
+44 (0)7818 430877
j.wilson@autolus.com
Susan A Noonan
S.A. Noonan Communications, LLC
+1 212 966 3650
susan@sanoonan.com
=----------------------------------------------------------------------------------------------------------------------
ISIN: GB00BD045071
Category Code: MSCH
TIDM: ARIX
LEI Code: 213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.: 93366
EQS News ID: 1167351
End of Announcement EQS News Service
=------------------------------------------------------------------------------------
(END) Dow Jones Newswires
February 10, 2021 04:00 ET (09:00 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024